Literature DB >> 8344999

Amphotericin B and its delivery by liposomal and lipid formulations.

C Gates1, R J Pinney.   

Abstract

In recent years, new formulations of the original amphotericin B preparation (Fungizone) have been devised in order to overcome toxicity problems that frequently occur. These preparations represent an improved method of drug delivery, with an increased therapeutic index and a decrease in toxicity to mammalian cell membranes. The new formulations have different physico-chemical characteristics and differ in pharmacokinetic parameters. Their effects must be compared with conventional amphotericin B to ascertain potential roles in future antifungal therapy.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8344999     DOI： 10.1111/j.1365-2710.1993.tb00605.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN： 0269-4727            Impact factor:   2.512


  20 in total

1.  A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections.

Authors:  A Adedoyin; C E Swenson; L E Bolcsak; A Hellmann; D Radowska; G Horwith; A S Janoff; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Authors:  G W Boswell; I Bekersky; D Buell; R Hiles; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 3.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

4.  Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits.

Authors:  E H Kwong; M Ramaswamy; E A Bauer; S C Hartsel; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

Review 5.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 6.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

7.  Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.

Authors:  A Ayestarán; R M López; J B Montoro; A Estíbalez; L Pou; A Julià; A López; B Pascual
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Enhanced encapsulation of amphotericin B into liposomes by complex formation with polyethylene glycol derivatives.

Authors:  K Moribe; E Tanaka; K Maruyama; M Iwatsuru
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

9.  Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.

Authors:  K M Wasan; A L Kennedy; S M Cassidy; M Ramaswamy; L Holtorf; J W Chou; P H Pritchard
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.

Authors:  Verica Risovic; Michael Boyd; Eugene Choo; Kishor M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.